Skip to main content
Suchitra Acharya, MD, Oncology, New Hyde Park, NY

SuchitraSAcharyaMD

Oncology New Hyde Park, NY

Professor, Pediatrics, Hofstra Northwell School of Medicine; Director Hemostasis and Thrombosis Center, Northwell Health

Dr. Acharya is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Acharya's full profile

Already have an account?

  • Office

    269-01 76th Ave
    Suite 255
    New Hyde Park, NY 11040
    Phone+1 718-470-3460
    Fax+1 718-343-4642

Education & Training

  • New York Presbyterian Hospital (Cornell Campus)
    New York Presbyterian Hospital (Cornell Campus)Fellowship, Pediatric Hematology/Oncology, 1996 - 1999
  • Westchester Medical Center
    Westchester Medical CenterResidency, Pediatrics, 1993 - 1995
  • Seth G.S. Medical College
    Seth G.S. Medical CollegeClass of 1985

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 1996 - 2026
  • CT State Medical License
    CT State Medical License 2006 - 2007
  • NJ State Medical License
    NJ State Medical License 2007 - 2007
  • American Board of Pediatrics Pediatric Hematology-Oncology

Clinical Trials

Publications & Presentations

PubMed

Abstracts/Posters

  • Assessment of Provider Practices Regarding Management of VTE in Pediatric Leukemia
    Suchitra Acharya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
  • Provider Practices Regarding Prophylactic Anticoagulation in Children with Leukemia
    Suchitra Acharya, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019

Press Mentions

  • Marstacimab Gets FDA Nod for Hemophilia a or B Without Inhibitors
    Marstacimab Gets FDA Nod for Hemophilia a or B Without InhibitorsOctober 11th, 2024
  • FDA Approves First Once-Weekly Drug Treatment Regimen for Hemophilia
    FDA Approves First Once-Weekly Drug Treatment Regimen for HemophiliaOctober 11th, 2024
  • U.S. FDA Approves Pfizer’s HYMPAVZI™ (Marstacimab-Hncq) for the Treatment of Adults and Adolescents with Hemophilia a or B Without Inhibitors
    U.S. FDA Approves Pfizer’s HYMPAVZI™ (Marstacimab-Hncq) for the Treatment of Adults and Adolescents with Hemophilia a or B Without InhibitorsOctober 11th, 2024
  • Join now to see all